Emerald (EEX) Q1 2025 earnings summary

Executive summary

• Achieved double-digit revenue and adjusted EBITDA growth in Q1 2025, with revenue up 10.7% year-over-year to $147.7 million and adjusted EBITDA up 34.7% to $53.6 million, driven by organic growth, acquisitions, and portfolio optimization.

• Net income rose 39.1% to $15.3 million, reflecting higher operating income and improved margins despite increased non-recurring financing fees and tax provisions.

• Major acquisitions included Insurtech Insights and regulatory approval for This Is Beyond, expanding global and luxury event offerings.

• Share repurchase program expanded, with $8.8 million repurchased in Q1 and a new $25 million authorization through year-end 2025.

• Full-year 2025 guidance reaffirmed for $450–$460 million in revenue and $120–$125 million in adjusted EBITDA.

Financial highlights

• Q1 2025 revenue was $147.7 million, up 10.7% year-over-year, with organic revenue growth of 5.6% to $139.2 million.

• Adjusted EBITDA (excluding insurance proceeds) rose to $53.6 million, with a margin of 36.3%.

• Net income was $15.3 million, up from $11.0 million in Q1 2024; diluted EPS was $0.08.

• Free cash flow (excluding insurance proceeds) was $10.8 million, up from $3.8 million, with margin and underlying FCF improved by lower SG&A and higher operating income.

• Cash balance at March 31, 2025, was $276.8 million, with total liquidity of $386.8 million including a $110 million credit facility.

Outlook and guidance

• Full-year 2025 guidance reaffirmed: $450–$460 million in revenue and $120–$125 million in adjusted EBITDA.

• Guidance incorporates expected declines in international exhibitor revenue, especially from China and Canada, due to tariffs.

• Management expects sufficient liquidity for the next twelve months and to fund long-term obligations.

• Q1 performance and current sales pacing support confidence in meeting full-year targets.

• Management remains cautious due to macroeconomic uncertainty but optimistic about portfolio resilience and growth.